Is NERV or VERU more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Veru N/A -47.58% -35.83%

Does the media prefer NERV or VERU?

In the previous week, Veru had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Veru and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.04 beat Veru's score of 0.93 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LFCR or VERU?

In the previous week, Lifecore Biomedical had 3 more articles in the media than Veru. MarketBeat recorded 6 mentions for Lifecore Biomedical and 3 mentions for Veru. Veru's average media sentiment score of 0.93 beat Lifecore Biomedical's score of 0.20 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veru 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate VERU or MENS?

Veru currently has a consensus price target of $24.50, suggesting a potential upside of 895.93%. Given Veru's stronger consensus rating and higher possible upside, research analysts plainly believe Veru is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, VERU or MENS?

Jyong Biotech has lower revenue, but higher earnings than Veru. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.48 -$22.73M -$0.69 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is VERU or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Jyong Biotech N/A N/A N/A

Do analysts rate VERU or SBTX?

Veru currently has a consensus target price of $24.50, indicating a potential upside of 895.93%. Given Veru's stronger consensus rating and higher possible upside, research analysts plainly believe Veru is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERU or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Silverback Therapeutics N/A -29.62% -28.20%

Is UNCY or VERU more profitable?

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Veru N/A -47.58% -35.83%

Does the media prefer UNCY or VERU?

In the previous week, Unicycive Therapeutics had 9 more articles in the media than Veru. MarketBeat recorded 12 mentions for Unicycive Therapeutics and 3 mentions for Veru. Veru's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.07 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veru 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veru (VERU) Competitors

$2.46 +0.04 (+1.65%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.49 +0.03 (+1.06%)

As of 10/9/2026 07:50 PM Eastern

Compare

VERU vs. NERV, LFCR, MENS, SBTX, and UNCY

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Minerva Neurosciences (NERV), Lifecore Biomedical (LFCR), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), and Unicycive Therapeutics (UNCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Minerva Neurosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Veru has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market.

Minerva Neurosciences presently has a consensus price target of $10.33, suggesting a potential upside of 224.95%. Veru has a consensus price target of $24.50, suggesting a potential upside of 895.93%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Minerva Neurosciences' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Veru	N/A	-47.58%	-35.83%

In the previous week, Veru had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Veru and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.04 beat Veru's score of 0.93 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Veru has higher revenue and earnings than Minerva Neurosciences. Veru is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A

Summary

Veru beats Minerva Neurosciences on 9 of the 14 factors compared between the two stocks.

How does Veru compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 0.78%. Veru has a consensus target price of $24.50, indicating a potential upside of 895.93%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Veru has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.89	-$40.50M	-$1.07	N/A
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A

In the previous week, Lifecore Biomedical had 3 more articles in the media than Veru. MarketBeat recorded 6 mentions for Lifecore Biomedical and 3 mentions for Veru. Veru's average media sentiment score of 0.93 beat Lifecore Biomedical's score of 0.20 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veru has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Veru	N/A	-47.58%	-35.83%

Lifecore Biomedical has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Veru has a beta of -1.21, meaning that its stock price is 221% less volatile than the broader market.

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Veru beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does Veru compare to Jyong Biotech?

Veru (NASDAQ:VERU) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Veru has a beta of -1.21, indicating that its share price is 221% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

47.2% of Veru shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Veru had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for Veru and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.82 beat Veru's score of 0.93 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Veru	Positive
Jyong Biotech	Very Positive

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Jyong Biotech	N/A	N/A	N/A

Veru currently has a consensus price target of $24.50, suggesting a potential upside of 895.93%. Given Veru's stronger consensus rating and higher possible upside, research analysts plainly believe Veru is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has lower revenue, but higher earnings than Veru.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Summary

Veru beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

How does Veru compare to Silverback Therapeutics?

Veru (NASDAQ:VERU) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Veru currently has a consensus target price of $24.50, indicating a potential upside of 895.93%. Given Veru's stronger consensus rating and higher possible upside, research analysts plainly believe Veru is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Veru has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

In the previous week, Veru had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Veru and 0 mentions for Silverback Therapeutics. Veru's average media sentiment score of 0.93 beat Silverback Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the media.

Company	Overall Sentiment
Veru	Positive
Silverback Therapeutics	Neutral

Veru has higher revenue and earnings than Silverback Therapeutics. Veru is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Silverback Therapeutics' return on equity of -29.62% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Silverback Therapeutics	N/A	-29.62%	-28.20%

47.2% of Veru shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Veru beats Silverback Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Veru compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Unicycive Therapeutics presently has a consensus price target of $18.25, suggesting a potential upside of 344.04%. Veru has a consensus price target of $24.50, suggesting a potential upside of 895.93%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Unicycive Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market. Comparatively, Veru has a beta of -1.21, meaning that its stock price is 221% less volatile than the broader market.

In the previous week, Unicycive Therapeutics had 9 more articles in the media than Veru. MarketBeat recorded 12 mentions for Unicycive Therapeutics and 3 mentions for Veru. Veru's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.07 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veru has higher revenue and earnings than Unicycive Therapeutics. Veru is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	168.33	-$26.56M	-$1.75	N/A
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Veru	N/A	-47.58%	-35.83%

Summary

Veru beats Unicycive Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$41.94M	$12.40B	$7.25B	$13.30B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	-3.57	797.58	275.01	26.14
Price / Sales	2.48	751.21	582.85	87.88
Price / Cash	N/A	86.66	76.96	53.71
Price / Book	1.97	10.71	11.22	6.33
Net Income	-$22.73M	$2.84B	$3.50B	$382.15M
7 Day Performance	-1.99%	-0.94%	-0.89%	-1.40%
1 Month Performance	0.82%	-3.67%	-4.02%	-3.35%
1 Year Performance	-37.40%	-3.97%	7.13%	1.49%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	3.2591 of 5 stars	$2.46 +1.7%	$24.50 +895.9%	-37.4%	$41.94M	$16.89M	N/A	230	News Coverage Analyst Forecast
NERV Minerva Neurosciences	1.6364 of 5 stars	$3.40 flat	$10.33 +203.9%	+35.3%	$162.34M	N/A	N/A	7	News Coverage
LFCR Lifecore Biomedical	1.1699 of 5 stars	$6.52 +55.2%	$6.50 -0.3%	-0.8%	$158.98M	$128.87M	N/A	382	High Trading Volume
MENS Jyong Biotech	N/A	$1.97 -3.0%	N/A	-96.2%	$154.34M	N/A	N/A	27	Positive News
SBTX Silverback Therapeutics	N/A	$4.08 -1.7%	N/A	-63.5%	$147.12M	N/A	N/A	83	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors

VERU vs. NERV, LFCR, MENS, SBTX, and UNCY

How does Veru compare to Minerva Neurosciences?

Summary

How does Veru compare to Lifecore Biomedical?

Summary

How does Veru compare to Jyong Biotech?

Summary

How does Veru compare to Silverback Therapeutics?

Summary

How does Veru compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veru (VERU) Competitors

VERU vs. NERV, LFCR, MENS, SBTX, and UNCY

How does Veru compare to Minerva Neurosciences?

Which has more risk & volatility, NERV or VERU?

Do analysts recommend NERV or VERU?

Is NERV or VERU more profitable?

Does the media prefer NERV or VERU?

Do insiders and institutionals hold more shares of NERV or VERU?

Which has preferable valuation & earnings, NERV or VERU?

Summary

How does Veru compare to Lifecore Biomedical?

Do analysts rate LFCR or VERU?

Which has higher valuation and earnings, LFCR or VERU?

Does the media favor LFCR or VERU?

Is LFCR or VERU more profitable?

Which has more risk & volatility, LFCR or VERU?

Do insiders & institutionals have more ownership in LFCR or VERU?

Summary

How does Veru compare to Jyong Biotech?

Which has more volatility and risk, VERU or MENS?

Do insiders & institutionals believe in VERU or MENS?

Does the media refer more to VERU or MENS?

Is VERU or MENS more profitable?

Do analysts rate VERU or MENS?

Which has better earnings & valuation, VERU or MENS?

Summary

How does Veru compare to Silverback Therapeutics?

Do analysts rate VERU or SBTX?

Which has more risk & volatility, VERU or SBTX?

Does the media refer more to VERU or SBTX?

Which has higher valuation & earnings, VERU or SBTX?

Is VERU or SBTX more profitable?

Do insiders and institutionals believe in VERU or SBTX?

Summary

How does Veru compare to Unicycive Therapeutics?

Do insiders & institutionals hold more shares of UNCY or VERU?

Do analysts prefer UNCY or VERU?

Which has more risk & volatility, UNCY or VERU?

Does the media prefer UNCY or VERU?

Which has stronger earnings & valuation, UNCY or VERU?

Is UNCY or VERU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools